Is Valneva SE (VALN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 23.7% / 30% | 18.4% / 30% | 3.9% / 30% | 1.39% / 5% | ✓ HALAL |
| DJIM | 23.7% / 33% | 18.4% / 33% | 3.9% / 33% | 1.39% / 5% | ✓ HALAL |
| MSCI | 43.3% / 33% | 33.7% / 33% | 7.0% / 33% | 1.39% / 5% | ✗ NOT HALAL |
| S&P | 23.7% / 33% | 18.4% / 33% | 3.9% / 33% | 1.39% / 5% | ✓ HALAL |
| FTSE | 43.3% / 33% | 33.7% / 33% | 7.0% / 50% | 1.39% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -10.2% | |
| Operating Margin | -58.1% | |
| Net Margin | -66.0% | |
| Return on Equity (ROE) | -80.2% | |
| Return on Assets (ROA) | -11.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$53M |
| Free Cash Flow | -$57M |
| Total Debt | $207M |
| Debt-to-Equity | 195.2 |
| Current Ratio | 2.4 |
| Total Assets | $399M |
Price & Trading
| Last Close | $6.32 |
| 50-Day MA | $9.92 |
| 200-Day MA | $9.00 |
| Avg Volume | 18K |
| Beta | 1.3 |
|
52-Week Range
$5.43
| |
About Valneva SE (VALN)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Purification Calculator
As a halal stock with 1.39% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Valneva SE (VALN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Valneva SE is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Valneva SE's debt ratio?
Valneva SE's debt ratio is 23.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 43.3%.
Does Valneva SE require dividend purification?
Yes, Valneva SE has an impermissible income ratio of 1.39%, which means 1.39% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Valneva SE's key financial metrics?
Valneva SE has a market capitalization of $536M, and revenue of $175M. The company maintains a gross margin of -10.2% and a net margin of -66.0%. Return on equity stands at -80.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.